Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis

Balcer, L.J. , Galetta, S.L. , Calabresi, P.A. , Confavreux, C. , Giovannoni, G. , Havrdova, E. et al. (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304.

Frohman, E.M. , Stuve, O. , Havrdova, E. , Corboy, J. , Achiron, A. , Zivadinov, R. et al. (2005) Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol 62: 1519-1530.

Goodin, D.S. , Frohman, E.M. , GarmanyJr, G.P. , Halper, J. , Likosky, W.H. , Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the Ms Council for Clinical Practice Guidelines. Neurology 58: 169-178.

Kappos, L. , Bates, D. , Hartung, H.P. , Havrdova, E. , Miller, D. , Polman, C.H. et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6: 431-441.

Khatri, B. , Fox, R. , Koo, A.P. , Lynn, F. , Duda, P. , Jurgensen, S. et al. (2008) Plasma exchange accelerates the decline of serum natalizumab concentration in patients with multiple sclerosis: results of the Natalizumab PLEX study. Neurology 70: A227-A228.

Phillips, J.T. , O'Connor, P.W. , Havrdova, E. , Hutchinson, M. , Kappos, L. , Miller, D.H. et al. (2006) Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 67: 1717-1718.

Polman, C.H. , O'Connor, P.W. , Havrdova, E. , Hutchinson, M. , Kappos, L. , Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.

Rudick, R.A. , Miller, D. , Hass, S. , Hutchinson, M. , Calabresi, P.A. , Confavreux, C. et al. (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62: 335-346.

Stuve, O. , Marra, C.M. , Bar-or, A. , Niino, M. , Cravens, P.D. , Cepok, S. et al. (2006a) Altered CD4+/ CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63: 1383-1387.

Stuve, O. , Marra, C.M. , Jerome, K.R. , Cook, L. , Cravens, P.D. , Cepok, S. et al. (2006b) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59: 743-747.

Thompson, J.P. , Noyes, K. , Dorsey, E.R. , Schwid, S.R. and Holloway, R.G. (2008) Quantitative risk-benefit analysis of natalizumab . Neurology 71: 357-364.

Yousry, T.A. , Major, E.O. , Ryschkewitsch, C. , Fahle, G. , Fischer, S. , Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.